Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

irin.

  • Preclinical Data at EASL. On April 24, Anadys will present additional data on the preclinical profile of ANA598 at the EASL meeting in an oral presentation titled, "Preclinical Studies of ANA598 Combined with Other Anti-HCV Agents Demonstrate Potential of Combination Treatment." Anadys will present in vitro data showing that combinations of ANA598 with interferon-alpha, the protease inhibitor telaprevir and the nucleoside polymerase inhibitor PSI-6130 are synergistic. These studies also show that ANA598 retains activity against mutants known to confer resistance to other classes of direct antivirals, including protease inhibitors, nucleoside inhibitors and non-nucleosides that, through virtue of binding at a different site than ANA598, display a resistance profile distinct from that of ANA598. Genotypic mutations resistant to ANA598 will be shown to be fully susceptible to interferon-alpha, telaprevir and PSI-6130.

ANA773

ANA773 is an oral prodrug of a small molecule inducer of endogenous interferons that acts via the toll-like receptor 7 (TLR7) pathway. Anadys has completed 3-month toxicology and pharmacology studies in animals that demonstrated stable induction of interferon-dependent pathways at doses that led to no adverse findings. Anadys is exploring ANA773 in chronic Hepatitis C and oncology.

  • Phase I Clinical Trial in HCV. Patient dosing in a Phase I clinical trial of ANA773 in HCV has been completed through 1600 mg dosed every other day (QOD). Based on the encouraging data we have seen to date, Anadys has submitted an amendment to this study to test ANA773 at 2000 mg QOD. In the completed cohorts, HCV patients received oral ANA773 or placebo every other day over 28 days, at doses of 800 mg, 1200 mg or 1600 mg, with six subjects receiving
    '/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... Aug. 30 Pressure,BioSciences, Inc. (Nasdaq: ... has been,issued its first patent by the ... Biomolecular Complexes" (Number,2,259,318), this issuance extends the ... patents previously issued in the United States,Japan, ...
... SOUTH SAN FRANCISCO, Calif., Aug. 30 VaxGen,Inc. ... filed with the,Securities and Exchange Commission (SEC) its ... December 31, 2006 and Quarterly Reports on Form ... reports can be found at the link titled,"SEC ...
... of the FDA,s,Cooperative Research and Development Agreement (CRADA) ... (FDA) on August 23, 2007, in a,presentation focusing ... at,the Third Annual Regulatory and Compliance Symposium -- ... was held at Harvard University. Helen Winkle, ...
Cached Biology Technology:Pressure BioSciences, Inc. Issued First Patent in Canada 2Pressure BioSciences, Inc. Issued First Patent in Canada 3VaxGen Files 2006 Financial Statements and Provides Cash Update 2FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard 2FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard 3
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... some of North Africa,s major droughts of centuries past, ... the year 1179. The first multi-century drought reconstruction ... severe droughts during the 13th and 16th centuries and ... An international research team figured out northwest Africa,s climate ...
... Spanish . A new model for manipulating vitamin ... Service (ARS) scientists who say it could help establish just how ... optimal growth and health. Newborn dairy calves get crucial vitamin ... the first few days after birth. Later, the neonatal calf ...
... 25, 2010An insightful and in-depth presentation of the most ... pediatric interstitial lung disease (ILD) is presented in a ... Pediatric Allergy, Immunology, and Pulmonology (PED), a peer-reviewed ... ). The entire issue is available free online. ( ...
Cached Biology News:20th century one of driest in 9 centuries for northwest Africa 220th century one of driest in 9 centuries for northwest Africa 3Model developed for manipulating vitamin D levels in calves 2Comprehensive overview of Children's Interstitial Lung Disease (chILD) in special issue of Pediatric Allergy, Immunology, and Pulmonology 2
... These handy dispensers save space ... hats, and other garb. They are ... small parts used in labs, processing ... static charges and the particles they ...
... Double staining is a technique used ... single tissue.(1-6) PicTure™-Double Staining Kit is a ... detecting two antigens simultaneously in the same ... sensitivity. The antigens can be identified using ...
... NOVOstar is an exciting product for cell-based ... assays required the use of expensive HTS ... scientists in the assay development stage. The ... cell-based assays as well as any other ...
... the DH-2000, but comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium ... of deuterium and tungsten halogen light sources in ... produces a powerful, stable output from 215-200 nm. ...
Biology Products: